Legal action over trastuzumab is also not Pfizer's first foray into legal battles over biosimilars; Pfizer launched the first biosimilar infliximab product (Inflectra) in the United States in October 2016, and has proactively litigated against Johnson & Johnson, sponsor of the reference infliximab (Remicade), claiming that Johnson & Johnson engaged in anti-competitive practices that were intended to block Inflectra from gaining formulary placement.